Previous 10 | Next 10 |
Gainers: Sintx Technologies (NASDAQ: SINT ) +71% . Ruhnn Holding Limited (NASDAQ: RUHN ) +29% . Jaguar Health (NASDAQ: JAGX ) +19% . T2 Biosystems (NASDAQ: TTOO ) +15% . OncoCyte Corporation (NYSEMKT: OCX ) +13% . Libbey (NYSEMKT: LBY ) +13% . Cyclerion Therapeutics (NASDAQ: CY...
Ultra-thinly traded Celyad ( CYAD -23.9% ) is down in early trade, albeit on turnover of only 3K shares, on the heels of its global offering of 2M ordinary shares via ~1.7M ADSs at $10/ADS and a concurrent private placement of ~283K ordinary shares in Europe and certain other ex-U.S...
MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the pricing of a global offering of 2,000,000 ordinary share...
Tocagen (NASDAQ: TOCA ) -82% after two-part immunotherapy flunks brain cancer study. More news on: Tocagen Inc., Adverum Biotechnologies, Inc., Celyad SA, Stocks on the move Read more ...
Gainers: Yuma Energy (NYSEMKT: YUMA ) +145% . T2 Biosystems (NASDAQ: TTOO ) +57% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +29% . Bicycle Therapeutics (NASDAQ: BCYC ) +25% . CARBO Ceramics (NYSE: CRR ) +23% . Luby's (NYSE: LUB ) +23% . CBL & Associates Properties (NYSE: CBL...
Celyad (NASDAQ: CYAD ) has filed a prospectus to offer up to 2M shares . More news on: Celyad SA, Healthcare stocks news, Read more ...
MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it intends to offer and sell, subject to market and oth...
Today, we want to share our analysis of Bellicum Pharmaceuticals ( BLCM ) with you. Over the last year, its stock largely fluctuated, falling from ~ $7 in September 2018 to $0.78 in August 2019. Recently, the company’s stock price grew by more than 20% after Baker Bros. disclosed its ...
MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of CYAD-01 produced with...
MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to participate at the following e...
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...